KKR.
Two full-cycle healthcare exits, Max Healthcare (~5x, 2018-2022) and JB Chemicals (36% gross IRR, 2020-2026), have been redeployed into five more India hospital and device platforms, leaving KKR's live India PE book roughly two-thirds healthcare by GW's reconstruction.
GW GP Score
KKR opened its India office in 2008 and has since deployed more than $13bn across close to 40 private equity and credit transactions, with more than half of that capital going out in the last five years (KKR, Feb 2025 insights note). The two dated proof points are healthcare, not diversification. Max Healthcare returned KKR's holding through three staged sales between September 2021 and August 2022 (₹2,956 Cr, ~₹3,300 Cr, ₹9,185 Cr), a combined ~5x on the 2018 entry at $900M enterprise value. JB Chemicals & Pharmaceuticals, bought for ₹3,750 Cr (54%, Jul 2020), was trimmed by ₹1,460 Cr (5.8%, Mar 2025) before Torrent Pharmaceuticals took the remaining 46.39% for $1.4bn under a Jun 2025 agreement that completed 21 Jan 2026, at a reported 36% gross IRR (Business Standard, Jun 2025). That capital has gone straight back into Indian hospital beds: Baby Memorial Hospital (70%, ₹2,000 Cr, Jul 2024), Healthcare Global Enterprises (54% rising to up to 77% via open offer, ~$400M, agreed Feb 2025) and, at €1.2bn enterprise value, the outright purchase of Medicover's 24-hospital, ~4,800-bed India network (agreed 6 Aug 2026, expected to close Q4 2026, with a further ₹3,000-4,000 Cr of growth capital committed). Five of the desk's seven live positions and, by GW's dollar-weighted reconstruction, roughly two-thirds of deployed India PE capital now sit in healthcare. Vini Cosmetics (Fogg, $625M, 2021) and the credit arm KKR India Financial Services (~$1bn of the $13bn total, with ADIA a minority holder since 2017) are the two exceptions to that concentration. Gaurav Trehan, who took over India PE from Sanjay Nayar in December 2020 and now also runs KKR's wider Asia-Pacific private equity business, is fundraising a $15bn Asia Fund V (launched Nov 2025) off the back of Fund IV's India-heavy realisations.
Re-up candidate: the realised-cash evidence is doing more work than the brand story.
Portfolio quality depends on a narrow theme; the right comp is concentration risk, not headline unicorn count.
No named analyst override yet; current view is generated from the scored dossier and should be refreshed when the next primary source lands.
HCG open-offer completion and KKR's final settled stake (54-77% range, not disclosed as of Sep 2026).
Medicover India deal close (targeted Q4 2026) and any CCI conditions attached.
Concentration: five of seven live India PE positions and roughly two-thirds of GW's estimated deployed capital sit in one sector (healthcare), leaving the book exposed to any single regulatory or reimbursement shock to Indian hospitals or devices.
Computed from current dossier sources; analyst override pending.
Scored on two real, dated, cash-settled exits (Max Healthcare, JB Chemicals) that anchor exit-realisation and capital-discipline, offset by a live book that has gone almost entirely into one sector with no disclosed performance yet: 0.25×78 + 0.30×85 + 0.15×70 + 0.15×76 + 0.15×74 = 78.
Graded underPrivate equity rubric v1.0→Control or near-control stakes across the live book (Vini, Healthium, BMH, HCG, Medicover); Infinx is the one minority position; earnings quality of the newer entries undisclosed
Two full, dated cash exits: Max Healthcare ~5x (2018-2022) and JB Chemicals 36% gross IRR (2020-2026), both strategic/block sales, not partial marks
Repeatable healthcare-consolidation thesis, but Max Healthcare's return carries a hospital-sector re-rating component GW cannot fully separate from operating improvement (E)
Fund V ($15bn target) launched Nov 2025 straight off Fund IV's India realisations; JB Chemicals entry (₹745/share, 2020) vs exit (₹1,600-1,639/share, 2025) discloses a favourable entry multiple
Clean, telegraphed 2020 leadership handover (Nayar to Trehan) with no churn since, but Trehan now carries a dual India-CEO/Asia-PE-co-head mandate and no named India deputy is publicly identified
Asset quality & control 25% · Exit realisation 30% · Value creation 15% · Capital discipline 15% · Franchise stability 15% — the five contributions above sum to 78. Raw scores compare within private equity; across cohorts compare the tier. See the full GP Score methodology · compare this firm →
Positive catalysts and/or re-up evidence exceed the visible risks, but the score should move only after the named proof lands.
Latest fund closes at or above target with named institutional LP support.
Medicover India deal close (targeted Q4 2026) and any CCI conditions attached.
HCG open-offer completion and KKR's final settled stake (54-77% range, not disclosed as of Sep 2026).
Scored on two real, dated, cash-settled exits (Max Healthcare, JB Chemicals) that anchor exit-realisation and capital-discipline, offset by a live book that has gone almost entirely into one sector with no disclosed performance yet: 0.25×78 + 0.30×85 + 0.15×70 + 0.15×76 + 0.15×74 = 78.
Concentration: five of seven live India PE positions and roughly two-thirds of GW's estimated deployed capital sit in one sector (healthcare), leaving the book exposed to any single regulatory or reimbursement shock to Indian hospitals or devices.
HCG open-offer completion and KKR's final settled stake (54-77% range, not disclosed as of Sep 2026).
Catalyst exposure · latest source pressure
Recent public evidence mapped to this GP. Read this before reading the position table: it is where the score can move next.
Keep the file warm; current events cut both ways or are not yet material enough to move score.
Attribution0 positive catalyst(s), 0 pressure catalyst(s); top driver: monthly refresh only.
The funds
$796bn global AUM (30 Jun 2026, +16% YoY); $13bn+ deployed in India PE and credit since 2008 across 3 tracked vehicles.
| Vehicle | Vintage | Size | Stage | Note |
|---|---|---|---|---|
| KKR Asian Fund V | 2025 (raising)Recovery / IPO window | Target $15bn | Pan-Asia control + growth PE | Launched fundraising Nov 2025; India a top-three country allocation per prior vintages |
| KKR Asian Fund IV | 2021Peak frenzy | $15bn | Pan-Asia control + growth PE | Exceeded $12.5bn target; source of the Max Healthcare and JB Chemicals India realisations |
| KKR India credit platform (KIFS/KIAFPL) | 2009Foundation era | ~$1bn+ deployed (GW estimate, E) | Structured & alternative credit | ADIA took a minority stake in the platform in 2017 |
Fund analytics · LP underwriting screen
Computed from the public dossier: vehicle cadence, realised exits, mark drift, concentration and franchise stability. All computed signals are GW estimates.
Latest vehicle is still in market or not publicly closed.
2 visible exit events since Jul 2024.
Latest vehicle is still in market or not publicly closed.
1 up / 6 flat / 0 down tracked signals.
No senior departure flagged in key people.
1 up / 6 flat / 0 down
2 events since Jul 2024
Largest tracked active exposure
Higher spread = less balanced franchise
Exit-led repricing; entry discipline decisive
Cycle-top entry marks; the vintage still being digested
Pre-unicorn pricing; discovery-cost entries
At least one cited source is dated 2026.
5 visible events tracked.
7 representative positions tracked.
No departure signal structured.
Fund-level DPI/TVPI is usually not public; proxy remains estimated.
Peer median 3 · -1
Peer median 2 · -2
Peer median 89 · +0
Peer median 38 · -24
Peer median 0 · +0
Diligence agenda · how this view can change
The live research question, the proof required, and the source standard. This prevents a GP score from becoming a stale label.
The latest vehicle is raising, unclosed or stale against the current deployment cycle.
Current · At least one cited source is dated 2026.
Medicover India deal close (targeted Q4 2026) and any CCI conditions attached.
Track first/final close, LP quality, target-vs-close delta and mandate shift.
Medicover India deal close (targeted Q4 2026) and any CCI conditions attached.
HCG open-offer completion and KKR's final settled stake (54-77% range, not disclosed as of Sep 2026).
Evidence quality · source file health
How hard the public record is beneath this view: source mix, freshness, low-confidence fields and the next source action.
Low-confidence fields: Portfolio data, Team data.
21 total sources · 33% primary
At least one cited source is dated 2026.
KKR Q2 2026 earnings release (AUM $796bn)
Upgrade Portfolio data evidence before changing the score.
Source tiering follows Gravitywell policy: primary = filing/regulator/company disclosure, secondary = reputable media or research, E = Gravitywell estimate. Evidence score is a GW control metric, not an external rating.
The position book
Healthcare-concentrated control book; 7 live India PE positions tracked below.
| Company | Sector | Entered | Entry stage | Status | 12-mo signal | Latest read |
|---|---|---|---|---|---|---|
| Vini Cosmetics (Fogg) | Consumer & Commerce | 2021 | Buyout, $625M / ₹4,600 Cr | Private | → | Founder-family (Patel) retains a minority stake and chairmanship; no disclosed exit or re-rating since 2021 |
| Healthium Medtech | Healthcare | 2024 | Buyout from Apax Partners, ~$839M / ₹7,000 Cr | Private | → | Agreed May 2024, expected to close Q3 2024; controlling stake via a KKR-fund SPV |
| Baby Memorial Hospital | Healthcare | 2024 | Buyout, 70% / ₹2,000 Cr | Private | → | Kerala-based 1,000-bed multi-specialty chain; KKR's re-entry into Indian hospitals post Max Healthcare |
| Healthcare Global Enterprises (HCG) | Healthcare | 2025 | Buyout from CVC Asia V, 54% + open offer up to 77%, ~$400M / ₹3,465 Cr | Public | → | Agreed Feb 2025 at ₹445/share; CCI cleared May 2025; final held stake depends on open-offer take-up (not separately disclosed as of Sep 2026) |
| Infinx (Infinx Services) | Healthcare | 2024 | Minority, ~$150M / ₹1,250 Cr | Private | → | Healthcare revenue-cycle-management BPO for the US market; Norwest Venture Partners a co-investor; sector forced to Healthcare over SaaS & Dev Tools given its RCM business model |
| Medicover India (hospitals) | Healthcare | 2026 | 100% buyout, €1.2bn / ₹13,188 Cr EV | Private | ▲ | Agreed 6 Aug 2026, expected to close Q4 2026; 24 hospitals, ~4,800 beds across Telangana, AP, Maharashtra, Karnataka; +₹3,000-4,000 Cr committed growth capital |
| KKR India Financial Services (KIFS/KIAFPL) | Fintech | 2009 | Balance-sheet NBFC platform | Private | → | RBI-registered systemically important NBFC; >$5bn deployed across ~150 India credit deals to date (KKR); ADIA a minority shareholder since 2017 |
Representative tracked positions reconstructed from public disclosures: not the full book. 12-mo signal is a GW estimate of mark direction from round/exit prints (E). Ownership stakes are not shown: not reliably public.
Sector exposure · where the book leans
Share of the tracked active book by normalized sector (GW estimate): read against our sector dossiers for crowding.
New cheques · 2025-26
Every disclosed India PE deal since KKR's 2024 return to hospitals has been healthcare: two hospital-network buyouts (Baby Memorial, Medicover), one listed-oncology control deal (HCG), one device-maker carve-out from a rival sponsor (Healthium) and one healthcare-BPO minority (Infinx). The pattern repeats the Max Healthcare playbook, control-stake hospital consolidation, at more than 2.5x the capital committed to that single 2018 deal.
Expected close Q4 2026
Realisation · are LPs getting paid?
Two dated, cash-settled realisations anchor the India franchise's track record: Max Healthcare's staged 2021-22 exit (~5x on a 2018, $900M entry) and JB Chemicals' strategic sale to Torrent completed Jan 2026 (36% gross IRR on a 2020 entry). Both are full exits with disclosed pricing, not partial marks, the strongest evidence GW has that the India PE book actually returns cash rather than rolling paper gains.
Torrent Pharmaceuticals completed the purchase of the remaining 46.39% for $1.4bn (agreed 29 Jun 2025); NCLT cleared the follow-on merger 6 Jul 2026. Reported 36% gross IRR on the Jul 2020 entry.
5.8% sold via open-market block trades for ₹1,460 Cr, cutting the holding to 47.88% ahead of the full exit.
Final 27.5% sold for ~₹9,185-9,416 Cr (reports vary); at the time the largest 25%+ block sale by a PE fund in India.
Radiant (KKR affiliate) sold 10% for ~₹3,300 Cr at ₹340/share.
8.74% sold for ₹2,956 Cr, the first tranche of the phased exit.
2020 entry (₹3,750 Cr, 54%) to Jan 2026 completion of the Torrent sale; Business Standard, Jun 2025
2018 entry ($900M, 49.7%) to Aug 2022 full exit across three block sales
$796bn at 30 Jun 2026 vs prior-year quarter; fee-paying AUM $638bn, +15% YoY
KKR insights note, Feb 2025; healthcare now the dominant share of new deployment
The realised numbers, two full exits at a combined ~5x and 36% IRR, are the strongest data points in the India book; nothing comparable is disclosed for the newer healthcare positions (Healthium, Infinx, BMH, HCG, Medicover), all still marked at cost as of Sep 2026. GW reads the pace of redeployment into a single sector as a bet that the Max Healthcare re-rating repeats, not a diversification of that risk.
What they're doing
Control and majority-stake buyouts in India healthcare: hospitals (Baby Memorial, HCG, Medicover), devices (Healthium) and healthcare BPO (Infinx), repeating the Max Healthcare model of consolidating fragmented regional operators under one balance sheet.
Full-cycle exits via strategic sale (JB Chemicals to Torrent) or staged block sales into listed strength (Max Healthcare), not IPO-led monetisation.
A standing India credit platform (KIFS/KIAFPL) alongside the PE book, funded partly by outside LPs (ADIA) rather than solely KKR's own credit funds.
Fund-level cadence tied to the pan-Asia vehicle (Fund IV to Fund V) rather than a dedicated India fund; India competes for capital against China, Japan, Korea and Southeast Asia within each raise.
What can break
Concentration: five of seven live India PE positions and roughly two-thirds of GW's estimated deployed capital sit in one sector (healthcare), leaving the book exposed to any single regulatory or reimbursement shock to Indian hospitals or devices.
None of the 2024-26 healthcare entries (Healthium, Infinx, BMH, HCG, Medicover) has a disclosed exit, IRR or public mark yet: the desk's strong realised numbers are entirely in two closed positions, not the current book.
Key-person concentration in Gaurav Trehan, who holds both the India CEO role and the wider Asia-Pacific PE co-head mandate, with no publicly named India deputy identified in this research.
The Max Healthcare return partly rode a 2018-2022 re-rating of listed Indian hospital stocks; GW cannot separate the multiple-expansion component from operating improvement using public disclosures alone (E).
HCG open-offer completion and KKR's final settled stake (54-77% range, not disclosed as of Sep 2026).
Medicover India deal close (targeted Q4 2026) and any CCI conditions attached.
KKR Asian Fund V ($15bn target, launched Nov 2025) final close size and disclosed India allocation.
Whether KKR names a dedicated India PE deputy under Gaurav Trehan given his expanded Asia-Pacific mandate.
Point-in-time discipline: these are the open items we could not verify at the current vintage. They get resolved: confirmed, corrected or dropped, at the next monthly refresh, never silently.
The takes · one screen, three readers
KKR has now booked two of the largest, cleanest healthcare exits in Indian PE history (Max Healthcare's ~5x, JB Chemicals' 36% IRR) and is redeploying that exact playbook at greater scale: Medicover alone is 2.5x the capital Max Healthcare took in 2018. If Indian hospital and device multiples hold, the newer positions have a proven template to follow.
Every India PE dollar committed since 2024 has gone into one sector, and none of those five positions (Healthium, Infinx, BMH, HCG, Medicover) has a disclosed mark, IRR or exit. The desk's performance story is entirely retrospective; nothing in the live book has been tested by a public sale yet.
Sourcing. Every figure is sourced and dated. We tier provenance: Primary (official, regulatory, exchange or company filings), Secondary (tier-1 industry research and reputable media), and GW estimate (our own reconstruction or opinion, labelled, never presented as external fact). We prefer primary where it exists, reconcile divergent prints to cited ranges, and hold every number point-in-time: dated, and never silently restated; revisions publish as dated changes.
Fact vs opinion. Facts vs opinion: market sizes, official prints, prices, named deals and agency ratings are sourced facts (Primary/Secondary). Scores, grades, purity weights, scenario paths and indicative sparkline points are Gravitywell's analytical opinion (GW estimate): labelled, not presented as external data.
GW GP Scores are research opinions, not investment advice, not a solicitation, and not an assessment under any SEBI regulation. Dossiers are compiled from public sources believed reliable; firms named did not participate and figures marked E are Gravitywell estimates. Point-in-time: dated to the vintage shown and never silently restated.